SciHub
文献互助
期刊查询
2024影响因子
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
白白嫩嫩
Lv7
125
3970 积分
2021-10-09 加入
最近求助
最近应助
互助留言
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
10天前
已完结
Real-world surgical treatment patterns and clinical outcomes in patients with stages IA–IIIA non-small cell lung cancer: a retrospective multicentric observational study involving 11,958 patients
17天前
已完结
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
17天前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
18天前
已完结
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
18天前
已完结
Neoadjuvant and Adjuvant Pembrolizumab for the Treatment of Early-Stage Resectable Non-small Cell Lung Cancer An Editorial Regarding the Interim Data Analysis of the KEYNOTE-671 Phase III Trial of Neoadjuvant and Adjuvant Pembrolizumab
18天前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
1个月前
已完结
Single-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis
1个月前
已完结
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone
1个月前
已完结
Comment on “Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC”
1个月前
已完结
没有进行任何应助
速度真快
18天前
题目不一样
1个月前
已经下载到了【积分已退回】
4个月前
点赞
1年前
帮大忙了
1年前
速度真快
2年前
下载到了【积分已退回】
2年前
点赞
2年前
感谢
2年前
写错了【积分已退回】
2年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论